慢性肾脏病的药物治疗新进展  

Recent advances in drug therapy for chronic kidney disease

作　　者：樊辛 李路瑶 方琳 王莎 杨向东[1] Fan Xin;Li Luyao;Fang Lin;Wang Sha;Yang Xiangdong(Department of Nephrology,Qilu Hospital of Shandong University,Jinan 250012,China)

机构地区：[1]山东大学齐鲁医院肾内科,济南250012

出　　处：《中华肾脏病杂志》2025年第2期138-143,共6页Chinese Journal of Nephrology

基　　金：国家自然科学基金(82070746、82270775)。

摘　　要：慢性肾脏病(chronic kidney disease,CKD)是全球范围内的重大公共卫生问题。近年来,许多新型药物在CKD治疗中显示出显著疗效。钠-葡萄糖共转运蛋白2抑制剂、非甾体类盐皮质激素受体拮抗剂和胰高血糖素样肽-1受体激动剂通过不同机制改善了CKD患者的肾脏结局,同时在心血管结局等方面也展现出良好的治疗效果。内皮素受体拮抗剂等新型药物也逐渐积累了延缓肾病的临床证据,新型靶点不断开发。本文综述了这些药物在CKD治疗中的最新研究进展,为CKD的药物治疗提供新思路和参考依据。Chronic kidney disease(CKD)is a significant global public health issue.In recent years,several new drugs have shown substantial efficacy in CKD treatment.Sodium-glucose cotransporter 2 inhibitors,nonsteroidal mineralocorticoid receptor antagonists,and glucagon-like peptide-1 receptor agonists improve renal outcomes in CKD patients through various mechanisms,and also demonstrate favorable effects on cardiovascular outcomes.Novel agents,including endothelin receptor antagonists,are accumulating clinical evidence for delaying kidney disease progression,with ongoing development of new therapeutic targets.This article reviewed the latest research progress of these drugs in CKD treatment,offering new perspectives and reference points for comprehensive CKD management.

关 键 词：肾功能不全 慢性 销钠-葡萄糖共转运蛋白2抑制剂 盐皮质激素受体拮抗剂 胰高血糖素样肽-1受体激动剂 药物治疗 

分 类 号：R692[医药卫生—泌尿科学]